Aspira Women’s Health 

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aspira Women's Health (AWH) sees robust growth and innovation in Q1 2024

Aspira Women's Health (AWH) reported strong performance in Q1 2024, driven by significant growth in test volumes and improvements in financial metrics. The company's focus on innovation and collaboration underscores its commitment to advancing women's health diagnostics. While challenges in funding persist, AWH's strategic initiatives and market opportunities position it for continued growth and success in the future.

Aspira Women's Health achieves record test volumes amidst cost challenges

AWH reported strong performance in test volumes and revenue growth in Q2 2024.
While facing challenges with margins and costs, the company is actively addressing them.
Opportunities lie in product development, market expansion, and cost control measures.
Overall, AWH is strategically positioned for growth and innovation in the women's health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, announced today that it has entered into agreements to provide its testing services to Medicaid plan members in the state of New Hampshire and Washington, D.C equaling nearly a half million covered lives. The state of New Hampshire covers 200,000 lives and Washington D.C. covers 265,000 lives under their respective Medicaid programs. With the addition of these plans, Aspira is now credentialed to provide its OVA1 testing to nearly 80% of the Medicaid population in the U.S., totaling approximately 60 million lives.

Aspira Women's Health Announces the Addition of 465,000 Covered Lives Through Medicaid Credentialing

Vinco Ventures

Camber Energy

Progenity

Senseonics Holdings

Short squeeze penny stocks to watch today. The post Best Penny Stocks To Buy For A Short Squeeze?

Best Penny Stocks To Buy For A Short Squeeze? 5 To Watch Today

Aspira Women's Health Inc. (AWH) CEO Valerie Palmieri on Q3 2021 Earnings Call Transcript

Aspira (AWH) delivered earnings and revenue surprises of -12.50% and 11.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aspira (AWH) Reports Q3 Loss, Tops Revenue Estimates

﻿ Total Revenue Increased 34% to $1.67 million; OVA1 Volume Grew 19% to 4,281 Units

Aspira Women's Health Reports Third Quarter 2021 Financial Results

Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Aspira (AWH) Q3 Earnings Expected to Decline

Aspira Women's Health has entered into partnership agreements with two of the largest U.S.-based women's health networks and two independent U.S. laboratories. Aspira Women's Health has entered into partnership agreements with two of the largest U.S.-based women's health networks and two independent U.S. laboratories.

Aspira Women's Health Executes Four Aspira SynergyTM Technology Transfer Agreements

AUSTIN, Texas, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29th, 2021.

Aspira Women's Health Inc. to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Signals Call to Action for Immediate Progress in Conquering Ovarian Cancer Signals Call to Action for Immediate Progress in Conquering Ovarian Cancer

Aspira Women's Health Kicks Off Ovarian Cancer Awareness Month by Further Establishing Itself as a Thought Leader in Ovarian Cancer

Aspira Women's Health's (AWH) CEO Valerie Palmieri on Q2 2021 Results - Earnings Call Transcript

Aspira (AWH) delivered earnings and revenue surprises of 0.00% and 5.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Aspira (AWH) Reports Q2 Loss, Tops Revenue Estimates

﻿ Total Revenue Increased 141% to $1.8 million; OVA1 Volume Grew 85% to 4,553 Accessions

Aspira Women's Health Reports Second Quarter 2021 Financial Results

Analysts Estimate Aspira (AWH) to Report a Decline in Earnings: What to Look Out for

AUSTIN, Texas, July 27, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that it will report financial results for the second quarter ended June 30, 2021 on Thursday, August 12, 2021, after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Aspira Women's Health Inc. to Report Second Quarter 2021 Financial Results on August 12

Aspira Women's Health (AWH) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Aspira Women's Health (AWH) is Oversold: Can It Recover?

AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) today announced its OVA1® risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health's Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nation's largest health care organizations. AIM's mission is to promote appropriate, safe, and affordable health care. As one of the nation's leading specialty benefits management firms, AIM helps improve the quality of care and reduces the cost for many of the most complex tests and treatments.

UPDATE -- Aspira Women's Health Inc. Announces Coverage for OVA1® in the AIM Specialty Health Laboratory Medicine Clinical Guidelines

AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for the event are below:

Aspira Women's Health Inc. to Participate in the William Blair Growth Stock Conference

Aspira Women's Health Inc. (AWH) CEO Valerie Palmieri on Q1 2021 Results - Earnings Call Transcript

Conference call scheduled for today, May13 at 4:30 p.m. ET Conference call scheduled for today, May13 at 4:30 p.m. ET

Aspira Women's Health Reports First Quarter 2021 Financial Results

New Team Addition Is a Thought Leader in Reimbursement and Diagnostics New Team Addition Is a Thought Leader in Reimbursement and Diagnostics

Aspira Women's Health, Inc. Expands Leadership Team with Industry Veteran

Earnings Preview: Aspira (AWH) Q1 Earnings Expected to Decline

Aspira Women's Health Inc. (AWH) CEO Valerie Palmieri on Q4 2020 Results - Earnings Call Transcript

Aspira (AWH) delivered earnings and revenue surprises of -1350.00% and 11.23%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Aspira (AWH) Reports Q4 Loss, Tops Revenue Estimates

Conference Call scheduled for today, March 25th at 4:30 p.m. ET Conference Call scheduled for today, March 25th at 4:30 p.m. ET

Aspira Women's Health Reports Fourth Quarter and Full Year 2020 Financial Results

AUSTIN, Texas, March 25, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced it has entered into an agreement with Dana-Farber Cancer Institute (DFCI), Brigham and Women's Hospital, and Medical University Lodz to evaluate their novel microRNA (miRNA) technology in combination with current AWH technologies, for the development of a highly sensitive and specific high-risk early detection test for ovarian cancer. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and is the only gender-specific cancer with an over 50 percent mortality rate impacting women of all ages and ethnicities.

Aspira Women's Health, Inc. Announces an Agreement for the Development and Commercialization of an Early-Detection Test for Identification of Ovarian Cancer

News for Aspira Women’s Health Stock (AWH)